logo
Dermatologists Say These 5 Changes Will Save Your Skin During Menopause

Dermatologists Say These 5 Changes Will Save Your Skin During Menopause

Yahoo2 days ago
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
What the heck is going on with my skin?
It's my firm belief that that this question will be uttered at some point by every woman going through menopause. That's because issues like dryness, volume loss, adult acne, and wrinkles can all be happening during this time. I should know—I'm there myself.
I've been fortunate to sidestep the hot flashes, the breast pain, and the brain fog (all common menopausal complaints), but my skin has changed. I never considered my complexion to be particularly problematic, but when I turned 50, my outer layer became a super-sensitive desert of dryness from head to toe. Dune's Arrakis has nothing on me.
So, what is going on with your skin at this time in life—and what can you do about it?
The hormonal fluctuations during perimenopause—the transition period leading up to your final monthly menstrual cycle—are what trigger breakouts and dryness, says Ellen Marmur, MD, a dermatologist and the founder of Marmur Medical. The maddening part is that often many of the skin issues that crop up at this age occur at the same time.
Meet the experts: Ellen Marmur, MD is a dermatologist and the founder of Marmur Medical. Mona Gohara, MD, is a dermatologist in Connecticut and a member of the Women's Health medical advisory board. Amy Wechsler, MD, is a board-certified dermatologist in New York City.
That was certainly the case for Melissa Mattola-Kiatos. 'I've had oily to combination skin my entire life, but in the year leading up to turning 50, things started changing drastically, and my skin became dry, itchy, and sensitive,' says Mattola-Kiatos, who lives outside Boston. 'I also had acne—and it was different from the pimples I had as a teen. Out of the blue, I'd get one major cystic pimple on my lower face.'
What's behind this trouble: Estrogen is decreasing (which increases dryness), while the production of hormones such as testosterone is dropping. And though you'd think greater dryness would reduce acne, a condition often associated with oily skin, you'd be wrong, says Mona Gohara, MD, a dermatologist in Connecticut and a member of the Women's Health medical advisory board. 'Sebum is just one factor in the acne equation,' she explains. 'Hormonal acne triggered by perimenopause results in cystic lesions that are deep in the skin and less reliant on oil production.'
Once you reach menopause, which officially happens after 12 consecutive months without a period, studies show that a lot of 'aging' issues start to show up. 'Estrogen drops when menopause hits, and this hormone is responsible for stimulating skin cells, such as the fibroblasts that make collagen and elastin,' says Dr. Gohara. 'So when estrogen decreases, there's also less collagen, elastin, hyaluronic acid, and ceramides being produced, which triggers dryness, wrinkling, and sagging.' In fact, collagen, the natural protein that keeps your skin plump and firm, can decrease by up to 30 percent in the five years immediately following the onset of menopause, according to one study.
Eera Sharma experienced these changes firsthand. 'I started noticing a small shift when I was in my 40s, but by the time I turned 50, I felt like 10 years of aging had shown up on my face,' says Sharma, who lives in Farmington, Connecticut. 'I wasn't bugged by the hint of a wrinkle and wanted to age gracefully, but by 53, I said, 'Screw that.' '
Besides the effects of menopause, there's cumulative UV damage, which shows up as brown spots, and the natural aging process, which slows skin-cell turnover and makes a complexion look dull. What we're dealing with is a perfect storm for your skin, but the good news is that you can actually prepare for it—and deal with it once it's past you. 'The key to a vital, healthy-looking glow during perimenopause and menopause is to have an approach that counteracts existing damage while preventing new damage,' says Dr. Gohara.
Here are the five most common menopausal skin woes—and what to do about them.
Hormonal acne
These aren't the zits you had in high school. Dr. Marmur calls these pimples, which typically pop up on the jawline, 'dry skin acne' because they're accompanied by a reduction in hyaluronic acid and ceramides. 'Estrogen is going down so testosterone is dominating, and this hormone imbalance during perimenopause triggers hormonal acne breakouts,' she says. The challenge is to clear pimples without drying out your skin further, so it's important to blend pore-clearing active ingredients with hydrating ones to keep your skin balanced. Dr. Gohara is a fan of topping off these actives with an hyaluronic acid-based moisturizer.
Use an acne product with to keep pores unclogged. This beta hydroxy acid is oil-soluble, so it cuts through oil-blocked pores to clear out oil, dead skin cells and dirt. It also has anti-inflammatory properties to help prevent irritation. 'I have two teenagers at home, so I stole some of their acne products, including a salicylic acid face wash that I use nightly,' says Mattola-Kiatos.
Try a retinoid. If the salicylic acid isn't clearing your skin, dermatologists recommend a prescription retinoid to keep pores clear by regulating skin cell turnover. (Plus, it builds collagen over time too.) 'I prescribe topical tretinoin to improve everything from skin laxity and wrinkles to breakouts,' says Amy Wechsler, MD, a board-certified dermatologist in New York City.
Opt for Rx meds. To step up treatment of stubborn hormonal acne, dermatologists prescribe an oral medication called spironolactone, which works by blocking the male hormones that trigger hormonal breakouts.
Fine Lines
As many women begin to notice, wrinkles first make an appearance during perimenopause due to collagen loss. If you have a proactive skin routine in place, including daily SPF to prevent the UV damage that destroys collagen and creates wrinkles, stay the course. The add these.
Again, reach for a retinoid. These vitamin A derivatives stimulate fibroblasts to produce more collagen and elastin. They also regulate skin cell turnover (which slows with age), keeping pores clear and skin smooth.
Pick up peptides. If you can't tolerate a retinol serum, use a collagen-boosting peptide product instead, suggests Dr. Gohara. These products work similar to vitamin A derivatives like retinol and prescription retinoids, but tend to be gentler.
Consider injections. Dr. Wechsler typically uses an injectable neuromodulator like Botox Cosmetic to smooth lines temporarily, as well as injectable fillers to add volume and soften wrinkles. Needles did the trick for Sharma: 'I had Botox a few months ago, and it diminished the appearance of my fine lines,' she says. 'I also got filler to lift my sagging skin and contour my face.'
Hair thinning
Hair and skin are two separate things, but considering scalp health is directly related to you hair health, it's only right to call this one out. 'Hair loss is probably one of the biggest issues that I see during perimenopause,' says Dr. Gohara. (About half of women experience accelerated hair loss at this stage in life.) It's a condition called 'androgenetic alopecia' or 'female pattern baldness,' and like hormonal acne, it's triggered by dropping estrogen levels that leave male hormones unopposed. 'In addition to causing breakouts, androgens may make you lose strands at the hairline and the crown of your head,' says Dr. Gohara.
That was Jaime Maser Berman's experience. The 47-year-old from New Jersey noticed thinning around her temples and part. 'Since this is where my gray roots are, it only exacerbated the look of thinness,' Berman says. She reached for the fast fix of root cover-up sprays, but there are preventive measures and medications you can take to stop the shedding.
Keep strands strong. Unfortunately, you may have to slow down or cut out some hair styling practices that cause damage. 'To prevent more hair loss, think about not over-processing the hair with bleach, or overusing hot tools like blow-dryers,' says Dr. Gohara. All that heat, pulling, and processing can weaken vulnerable strands by causing dryness, breakage, split ends, dullness, and more.
Try an OTC medication. Derms universally recommend topical minoxidil to curb hair loss. 'I suggest using the 5% solution, as opposed to the lower 2% version for women. It's more effective, and just as safe,' says Dr. Gohara. 'You apply this to your scalp twice a day, every single day to help grow hair locally.' One caveat: Once you stop using the product, your hair will start shedding again. This also might not treat other forms of hair loss, so make sure you run this option by your doctor before committing.
Seek a doctor's help. Dr. Gohara recommends seeing a dermatologist (yes, they treat hair issues, too) to get started with a plan of action. 'A higher dose of oral spironolactone can treat perimenopausal hair thinning, as well as hormonal acne. And in-office treatments such as platelet-rich plasma (PRP) injections can help stimulate hair growth too,' she says.Effaclar Salicylic Acid Acne Treatment
A serum made to treat acne, prevent new breakouts, and reduce the appearance of pores while preventing post-acne scarring.
$33.74 at amazon.comEvening Wear Ectoine + Retinoid Firming Night Cream
This retinol was created to address the look of fine lines and wrinkles that occur during menopause.
$80.00 at amazon.comThickening Shampoo
Suds up with a biotin- and keratin-infused shampoo that preserves what you've got and thicken it over time.
$7.34 at amazon.comDeep Hydration Restorative Cream
Dealing with hot flashes and dryness? This cream has ceramides and lipids, plus a red algae extract that cools skin on contact.
$132.00 at phosis.comUltra Gentle Balm
A blend of coconut oil, shea butter, and hyaluronic acid, this rich balm tackles dehydration all over, including the delicate skin of the vulva.
$19.99 at amazon.comFountain Of Glow Vitamin C Facial Serum
An 8 percent vitamin C serum that improves uneven tone and leaves a dewy finish.
$29.99 at ulta.com
Dryness
Getting back to my Arrakis-dry skin barrier. Plummeting estrogen not only impacts collagen and elastin, but the production of natural ceramides and HA. This means that the stratum corneum, the outermost layer of the skin, has a harder time keeping moisture in and irritants out.
You've heard of double cleansing? Now's the time for double- and triple-moisturizing. Look for hydrators like hyaluronic acid and glycerin, that bring water to the skin and emollient lipids like ceramides, squalene, or shea butter to help seal in that moisture.
Moisturize at every step. 'You need to transition to more hydrating and emollient formulas of everything—cleanser, body moisturizer, richer face creams, oils, and balms,' says Dr. Wechsler. And don't be afraid to layer. 'This is when you can slug and sandwich like crazy,' says Dr. Gohara. 'In menopause, you can't moisturize too much.'
Consider hormone therapy. Talk ing to your gynecologist about hormonetherapy can be a game changer for treating menopausal symptoms such as dry skin (in addition to vaginal dryness). So, if you experience either (or both), this option is worth trying.
Think twice about . 'While these are used to treat vaginal atrophy, I wouldn't prescribe them for facial antiaging,' Dr. Gohara says. 'The formulas use estriol, a weaker form of estrogen, but there's not enough science to show this ingredient is safe or efficacious on the face.'
Laxity
With less support from collagen and fat in the picture, your skin loses its firmness and begins to sag. 'There's also less elastin, the rubber band-y connective tissue that holds collagen in place so everything can flex and move,' explains Dr. Marmur. The result is a loss of volume in the face, the neck, and the jawline (the dreaded jowls!). Retinol and sunscreen are key, but there are other firming options.
Apply antioxidants. 'Estrogen also acts as an antioxidant that protects against free radical damage, so now that it's low, you should up your topical antioxidants, especially with vitamin C that's proven to help build collagen too,' says Dr. Gohara.
Consider these treatments. 'I'll do a series of fractionated laser treatments to help stimulate collagen and elastin formation over time,' says Dr. Marmur. 'This also works well on hyperpigmentation, dullness, and has a firming effect.' To firm skin on the lower face and neck, both experts recommend having an in-office procedure like Thermage, which uses radio frequency energy to stimulate collagen and elastin production and tighten skin. Sofwave is an ultrasound-based heat treatment that also stimulates the production of firming collagen deep in the dermis.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?
RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?

Yahoo

time2 minutes ago

  • Yahoo

RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?

The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally funded mRNA vaccine development. This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said. "We reviewed the science, listened to the experts, and acted," Secretary Robert F. Kennedy Jr. said in a press release on Tuesday. "The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." MORE: What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny Infectious disease experts told ABC News that mRNA technology has been very successful in preventing severe disease, hospitalization and deaths, especially during the COVID-19 pandemic, potentially affecting our preparedness for future pandemics. Ending mRNA vaccine development may also squash enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. "It's an excellent technology. It saved millions of lives and did it in a remarkably safe manner," Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told ABC News. "I think it's an unscientific move, a move that goes against existing science." Affecting future pandemic preparedness Last year, the federal government awarded Moderna $176 million to help expedite the development of an mRNA-based bird flu vaccine. Earlier this year, the vaccine manufacturer received an additional $590 million to speed up the development. However, in its press release, the HHS said it was cancelling the award, which has been issued by the Biomedical Advanced Research and Development Authority, to Moderna and the University of Texas Medical Branch. Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, told ABC News the wind-down is a blow to pandemic preparedness. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly. "The message to the companies will clearly be that they can no longer rely on the U.S. government for supporting any mRNA vaccine work, which is unfortunate, or even tragic, because the mRNA platform is one of the few that we have for pandemic threats in terms of something that we can make a vaccine for very quickly," he said. "So what, what Mr. Kennedy's and HHS' actions are doing is weakening our pandemic preparedness and weakening our biosecurity." The HHS also said it was terminating contracts with Emory University and Tiba Biotech. Researchers had been working on using mRNA technology to develop a nasal influenza vaccine. Emory has also been working on a dry powder inhaled mRNA-based treatment for influenza and COVID with TFF Pharmaceuticals, funded by BARDA. It's unclear if this is one of the 22 contracts that have been canceled. MORE: What to know about the next generation of COVID-19 vaccines Hotez said COVID-19 and influenza can have very severe consequences and that it's incorrect for Kennedy to mischaracterize them as harmless upper respiratory infections. "COVID and flu are not [only] upper respiratory infections," he said. "The reason we develop vaccines for COVID and flu is because they cause systemic illness and lower respiratory infections and cardiovascular illness. … This is part of the anti-vaccine playbook, to diminish the severity of the illness, and to say something like influenza or COVID is an upper respiratory infection, it's just very, very misleading." Cancer vaccines, HIV treatments mRNA technology has also been hailed as a potential vector for providing personalized cancer treatments and protection against HIV transmission. In February, a small preliminary study published in the journal Nature found a personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery. Additionally, a University of Florida study found an experimental mRNA vaccine paired with anticancer drugs boosted an anti-tumor response. Meanwhile, earlier this month, an early-stage clinical trial found two mRNA vaccine candidates triggered a strong immune response against HIV. Results from the trial showed that 80% of participants who received one of two vaccine candidates produced antibodies. Although antiretroviral therapy has been the standard treatment for HIV infection, and is effective in preventing transmission, it is hard to scale up worldwide due to its costs, making mRNA vaccines to be anti-HIV vaccine strategy, researchers from the U.S., Germany and Romania wrote in a commentary in June 2022. It's unclear if any of the BARDA contracts are specifically for cancer vaccines or HIV vaccine development, but Hotez said the real damage is denigrating mRNA technology. "What he's done is he's caused uncertainty among the American people about the safety and effectiveness of mRNA for any condition, including cancer," he said. "And in fact, mRNA technology is probably the most exciting technology we have now for cancer and also other non-communicable illnesses. … Even though he may not be canceling any cancer vaccine contracts through BARDA, it may have collateral deleterious in terms of squashing enthusiasm for the technology." Offit added that mRNA is not brand-new technology. mRNA was discovered independently by two teams in 1961, including French and American molecular biologists. Breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. This makes the technology primed for being used in other avenues, such as cancer vaccines, Offit said. "We now know a lot about mRNA," he said. "We know a lot about its safety. We know a lot about its safety in young children, including babies. We know a lot about it regarding gene therapy. We know a lot about this safety in terms of pregnant people, where that's often not the case with new technology." Offit went on, "So you have this background of information that enables you to move forward in a number of areas, involving babies or involving pregnant women. But there was an attempt by this administration to squelch that, to sit on all that for no good reason other than a political reason." Solve the daily Crossword

Retiree health care costs are climbing: What advisors need to know
Retiree health care costs are climbing: What advisors need to know

Yahoo

time2 minutes ago

  • Yahoo

Retiree health care costs are climbing: What advisors need to know

Health care costs for retirees just keep rising. A 65-year-old retiring in 2025 can expect to spend $172,500 on health care costs and medical expenses throughout retirement, according to a new survey from Fidelity. Financial advisors say ignoring that number can be a costly decision for retirees. Since Fidelity began tracking retiree health care costs in 2002 — when the estimated expense for a 65-year-old was just $80,000 — projected costs have steadily climbed, far outpacing inflation. In the past year alone, Fidelity reported a 4% increase in total expected health care spending for retirees. READ MORE: A health care planning checklist for financial advisorsLong-term care costs can derail retirement plans. Here's how to manage themWhy protecting wealth starts with planning for health careSocial Security is changing — here's how advisors are preparing The estimate includes out-of-pocket prescription drug costs, Medicare premiums and other medical expenses, such as co-payments and deductibles. Researchers did not include potential costs from other health care-related expenses, including over-the-counter medications, most dental services and long-term care. Many retirees have found themselves ill-equipped to handle those costs, according to Shams Talib, head of Fidelity Workplace Consulting. "Year after year, so many Americans underestimate how much they'll need to save to cover health care costs in retirement," Talib said. "We recognize the impact health care costs can have on retirement savings. With the right tools and guidance, pre-retirees and retirees alike can take greater control of their financial futures by beginning the planning process as soon as possible." Clearing up Medicare misconceptions Financial advisors say one of the biggest impediments to planning for health care costs in retirement is a misconception about the role of Medicare. Namely, that it will cover more medical expenses than it does. "When I have these conversations with clients, especially those who are unprepared, the first step is just helping them slow down," said Melissa Cox, owner of Future-Focused Wealth in Dallas, Texas. "There's often a mix of embarrassment and fear. Many say, 'I didn't know this was something I needed to think about.' We walk through Medicare together, clarify what's covered and what isn't, and start looking at how their current financial picture can support a more realistic health care forecast." That picture can start to look very different depending on how short they are of covering estimated medical expenses. "Sometimes we have to pivot, adjust spending, reframe goals or revisit timelines, but that's okay," Cox said. "What matters most is giving people a sense of control over something that felt out of reach." Encourage clients to plan early Preparing for health care costs in retirement can be a relatively straightforward process as long as clients start early, advisors say. Near-retirees have several cost-effective options to help cover expenses, including Medigap, long-term care insurance and life insurance with care-related riders. But for older retirees seeking coverage later, the process becomes more complex and often more expensive. According to Andrew Crowell, vice chairman of wealth management for D.A. Davidson in New York City, waiting too long to sign up for certain plans can make them difficult to obtain at all. "I've had some clients recently, in good health but in their 70s, who were looking for a little extra coverage. … Both of them [were] denied coverage because they couldn't pass a cognition test," Crowell said. "I have perfectly lucid conversations with them all the time, but the test that they were given was an individual over the phone reading a long list of words, and then they were asked to repeat back as many of the words they remembered hearing in the short space, and they froze up. They stammered through a few of them, and the insurance just denied them on that, and they have no aches, no pains, no typical aging stuff." If those same clients had tried to sign up for policies in their 50s or 60s, the situation would have looked very different, Crowell said. "If we had done that in their 60s or in their 50s — young, healthy — they would have qualified for a great preferred rate premium, and it wouldn't be an issue," he said. "Now they can try to reapply, but you know they're going to have the jitters from the minute they reapply, and they're probably going to freeze up again just because of that." Crowell, who has been working in the industry for over 30 years, said insurance companies are becoming more cautious when assessing people due to increasing longevity. When it's too late to start early Starting early is one of the most effective strategies in financial planning — and health care planning is no exception. But even for clients who come to an advisor later in life, there are still viable options to manage rising medical costs. "When I work with clients who are unprepared for these costs, the conversation often shifts to what they value most in their retirement plan," said Beau Kemp, a financial advisor at SwitchPoint Financial Planning in Lehi, Utah. "If the plan goes from looking good to looking constrained with the increased health care costs, we have to make some adjustments." Exactly what those adjustments look like depends on the client's lifestyle preferences, Kemp said. Clients set on maintaining their current lifestyle may need to delay retirement as they build up their savings. Others who are more concerned with retiring at a specific age may have to scale back their spending to make room for medical costs. "I rarely decrease the projected medical expenses in a plan because these costs are largely out of our control," Kemp said. "The focus needs to be on what we can control and if a client is comfortable with those adjustments. The goal is to create a plan that provides both financial security and peace of mind."

Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%

Yahoo

time2 minutes ago

  • Yahoo

Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 16% year on year to $811.1 million. The company's full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts' estimates. Its non-GAAP profit of $0.22 per share was significantly above analysts' consensus estimates. Is now the time to buy Exact Sciences? Find out in our full research report. Exact Sciences (EXAS) Q2 CY2025 Highlights: Exact Sciences will pay $75 million in cash (plus up to $700 million in additional payments) to secure the rights to Freenome's blood-based screening tools for colorectal cancer. Exact will also pay royalties up to 10% and $20 million annually for the next three years in joint R&D costs Revenue: $811.1 million vs analyst estimates of $773.1 million (16% year-on-year growth, 4.9% beat) Adjusted EPS: $0.22 vs analyst estimates of $0.05 (significant beat) Adjusted EBITDA: $138.2 million vs analyst estimates of $108.7 million (17% margin, 27.2% beat) The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.10 billion, a 1.8% increase EBITDA guidance for the full year is $465 million at the midpoint, above analyst estimates of $437.4 million Operating Margin: -0.3%, up from -3.8% in the same quarter last year Free Cash Flow Margin: 5.8%, down from 10.2% in the same quarter last year Constant Currency Revenue rose 16% year on year (12.4% in the same quarter last year) Market Capitalization: $8.93 billion 'The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,' said Kevin Conroy, chairman and CEO. Company Overview With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ:EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test. Revenue Growth A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Exact Sciences's 21.1% annualized revenue growth over the last five years was excellent. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Exact Sciences's annualized revenue growth of 13% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 13.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that Exact Sciences has properly hedged its foreign currency exposure. This quarter, Exact Sciences reported year-on-year revenue growth of 16%, and its $811.1 million of revenue exceeded Wall Street's estimates by 4.9%. Looking ahead, sell-side analysts expect revenue to grow 11.8% over the next 12 months, similar to its two-year rate. Despite the slowdown, this projection is noteworthy and indicates the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Although Exact Sciences broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 29.8% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Exact Sciences's operating margin rose by 29.2 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 16.6 percentage points on a two-year basis. If Exact Sciences wants to pass our bar, it must prove it can expand its profitability consistently. Exact Sciences's operating margin was negative 0.3% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although Exact Sciences's full-year earnings are still negative, it reduced its losses and improved its EPS by 33.1% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, Exact Sciences reported adjusted EPS at $0.22, up from negative $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Exact Sciences's full-year EPS of negative $0.33 will flip to positive $0.73. Key Takeaways from Exact Sciences's Q2 Results Exact Sciences will pay $75 million in cash and make up to $700 million in additional payments to secure the rights to Freenome's current and future blood-based screening tools for colorectal cancer. Exact will also pay sales royalties up to 10% and $20 million annually for the next three years in joint research and development costs. So do we think Exact Sciences is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store